Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Temsirolimus

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01155258Phase 1Completed

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Showing all 1 trials

Research Network

Common Treatments

  • Temsirolimus1
  • Vinorelbine Ditartrate1

Active Sponsors

  • University of Southern California1
  • Wyeth is now a wholly owned subsidiary of Pfizer1

Top Investigators

Related Conditions

  • Regional Gastrointestinal Carcinoid Tumor1
  • Stage Iii Renal Cell Cancer1
  • Stage Iii Endometrial Carcinoma1
  • Recurrent Uterine Sarcoma1
  • Recurrent Nonsmall Cell Lung Cancer1

Activity Timeline